A phase I clinical trial demonstrates that nfP2X7‐targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma
S.M. Gilbert; A. Gidley Baird; S. Glazer; J.A. Barden; A. Glazer; L.C. Teh; J. King
Author Information: Babraham Research Campus Biosceptre (U.K.) Limited
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.